Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AEOL 10150

Drug Profile

AEOL 10150

Alternative Names: AEOL-10150; MnTDEIP

Latest Information Update: 04 Nov 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Duke University; National Jewish Medical and Research Center
  • Developer Aeolus Pharmaceuticals Inc; National Institutes of Health (USA); National Jewish Medical and Research Center; United States Army Medical Research Institute of Chemical Defense; University of Colorado at Denver
  • Class Oxidoreductases; Porphyrins; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antioxidants; Free radical scavengers; Oxygen radical scavengers; Reactive oxygen species inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Amyotrophic lateral sclerosis; Acute radiation syndrome; Idiopathic pulmonary fibrosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute radiation syndrome
  • Preclinical Idiopathic pulmonary fibrosis
  • Suspended Amyotrophic lateral sclerosis
  • No development reported Acute lung injury; Gastrointestinal disorders; Lung disorders; Poisoning; Radiation injuries; Skin disorders; Solid tumours
  • Discontinued Chronic obstructive pulmonary disease; Cystic fibrosis; Diabetes mellitus; Mucositis; Spinal cord injuries; Stroke

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Acute-lung-injury in USA (SC)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Gastrointestinal-disorders in USA (SC)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Lung-disorders in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top